Navigation Links
2 Common Blood Pressure Meds Fare Equally in Preventing Heart Woes
Date:8/27/2012

MONDAY, Aug. 27 (HealthDay News) -- In a review that compared two common heart drugs against each other, researchers found no difference between atenolol and metoprolol in terms of preventing stroke, heart attack or heart failure for patients with high blood pressure who were placed on the medications.

Atenolol (Tenormin) and metoprolol tartrate (Lopressor) are beta blockers that are widely used to treat high blood pressure and heart problems. Previous research has suggested that atenolol might be less effective than other high blood pressure drugs for preventing cardiovascular events in patients with high blood pressure.

In this study, researchers reviewed the medical records of nearly 121,000 U.S. patients with high blood pressure but no history of heart disease who started taking one of the two drugs between 2000 and 2009. Atenolol was used by about 10 times more patients than metoprolol.

During a follow-up averaging about five years, there was no statistically significant difference in rates of heart attack, stroke or heart failure between the two groups of patients.

"In conclusion, we found no differences in [heart] event rates ... with either atenolol or metoprolol," said review author Emily Parker, of HealthPartners Institute for Education and Research in Minneapolis, and colleagues. However, the researchers added that the findings "should be interpreted cautiously, since there have been no trials comparing these two beta blockers directly."

Two experts not connected to the study said patients have many options for treating high blood pressure.

"Like many of my colleagues, I also use beta blockers as an add-on antihypertensive strategy for those patients being treated for hypertension and not yet having other cardiac problems," said Dr. David Friedman, chief of heart failure services at North Shore-LIJ's Plainview Hospital, in Plainview, N.Y. He added, however, that "when it comes to treating blood pressure alone, beta blockers have taken a back seat to other medications such as diuretics."

Dr. Kenneth Ong is acting chair of the department of medicine and cardiology at The Brooklyn Hospital Center, in New York City. He noted that there has been debate as to whether atenolol works as well as other drugs used to fight high blood pressure.

"While the [new] study is a retrospective analysis, it suggests that there may be no merit to changing atenolol to metoprolol tartrate," he said. "It will be important to verify these findings with a randomized, prospective trial."

The review was funded by the U.S. National Heart, Lung and Blood Institute, and was published online Aug. 27 in the Archives of Internal Medicine.

More information

The U.S. National Heart, Lung, and Blood Institute has more about treatment of high blood pressure.

-- Robert Preidt

SOURCES: Kenneth Ong, M.D., acting chair, department of medicine and cardiology, The Brooklyn Hospital Center, New York City; David Friedman, M.D., chief, heart failure services, North Shore-LIJ Plainview Hospital, Plainview, N.Y.; Archives of Internal Medicine, news release, Aug. 27, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Obese and overweight women face increased risk of recurrence of most common type of breast cancer
2. Rejected drug may protect against toxic substance common to Alzheimers and Parkinsons diseases
3. Condition Commonly Seen in Aging May Alter Brain Function
4. Alcohol advertising standards violations most common in magazines with youthful audiences
5. No difference in death rates among patients exposed to common rheumatoid arthritis drugs
6. Off-label drug use common, but patients may not know theyre taking them, Mayo finds
7. Diverted Medical Marijuana Use Common Among Teens: Study
8. Asthma Common Among Olympic Athletes
9. Common Skin Cancer a Chronic Condition, Study Says
10. Drug combo better for common type of metastatic breast cancer, UCI-led study finds
11. Asthma is the most common chronic disease among Olympic athletes
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
2 Common Blood Pressure Meds Fare Equally in Preventing Heart Woes
(Date:1/21/2017)... ... 21, 2017 , ... Salveo for life, a company that distributes an effervescent ... United States as part of its presence to expand its market reach. , Using ... the productions of nasty toxins as a result of drinking alcohol, eliminating those toxins ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... Phytocéane ... Indian Ocean, isolated from the rest of the world with ZANZIBAR SHOWER GEL. Inspired ... Phytocéane used key ingredients, Virgin Coconut Oil and moisturizing vegetal coral to create this ...
(Date:1/21/2017)... ... January 21, 2017 , ... Santa Rosa Orthopaedics (SRO) ... located at 167 Lynch Creek Way. The Petaluma office features three comfortable patient ... and rehabilitation services and on-site x-ray services. Two multi-specialist orthopaedic surgeons Dr. ...
(Date:1/20/2017)... , ... January 20, 2017 , ... Spectrum Aquatics Launches New ADA Portable Motion Trek ... space. Since the lift is mounted on wheels, it can be wheeled out of the ... kit, to fasten to the deck. "We have transformed the feedback from customers into specific ...
(Date:1/20/2017)... Raton, FL (PRWEB) , ... January 20, 2017 , ... ... seaweeds, botanicals and 100 percent pure essential oils, announced the company had a successful ... SC. , The annual ECRM event gives companies that work in the nutritional, sports ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Call and Webcast to Follow Vanda Pharmaceuticals Inc. (Vanda) ... for the fourth quarter of 2016 on Wednesday, February 15, 2017, ... ... ET on Wednesday, February 15, 2017, during which management will discuss ... corporate activities. To participate in the conference call, please dial 1-888-771-4371 ...
(Date:1/19/2017)... , Jan. 19, 2017  Stealth BioTherapeutics Inc. ... to treat mitochondrial dysfunction, today announced new additions to ... M.D., as Chief Medical Officer, and Daniel Geffken ... announced that Jim Carr , Pharm.D. has been ... "We are pleased to welcome Doug and Daniel to ...
(Date:1/19/2017)... CITY, Calif. , Jan. 19, 2017  Abaxis, ... company manufacturing point-of-care blood analysis instruments and consumables for ... conference call to discuss its financial results for the ... The call will be at 4:15 p.m. ET on ... results for the third quarter fiscal year 2017 after ...
Breaking Medicine Technology: